Login to Your Account



PPL Suffers Setback On News That Bayer Is Ending AAT Work

By Nuala Moran


Wednesday, June 25, 2003
LONDON - The prospect of a commercial return from the technology that produced Dolly the cloned sheep was effectively killed last week, when Bayer Healthcare LLC announced it was pulling the plug on the development of alpha-1-antitrypsin (AAT), being developed in a US$40 million collaboration with PPL Therapeutics plc. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription